Pembrolizumab versus placebo as adjuvant therapy in resected high -risk stage II melanoma: Phase 3 KEYNOTE-716 study.

被引：2
|
作者：
Carlino, Matteo S.
Ascierto, Paolo Antonio
Eggermont, Alexander M.
Gershenwald, Jeffrey E.
Grob, Jean Jacques
Hauschild, Axel
Kirkwood, John M.
Long, Georgina V.
Mohr, Peter
Robert, Caroline
Ross, Merrick I.
Scolyer, Richard A.
Sondak, Vernon K.
Yoon, Charles
Poklepovic, Andrew Stewart
Rutkowski, Piotr
Anderson, James R.
Ahsan, Sama
Ibrahim, Nageatte
Luke, Jason J.
机构：
[1] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia
[2] Univ Sydney, Blacktown Hosp, Melanoma Inst Australia, Sydney, NSW, Australia
[3] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[4] Gustave Roussy Canc Ctr, Paris, France
[5] Univ Paris Saclay, Paris, France
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Aix Marseille Univ, Marseille, France
[8] Univ Hautklin Kiel, Kiel, Germany
[9] Univ Pittsburgh, UPMC Hillman Canc Ctr, Melanoma Program, Pittsburgh, PA USA
[10] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[11] Royal North Shore Hosp, Sydney, NSW, Australia
[12] Mater Hosp, Sydney, NSW, Australia
[13] Elbe Kliniken Buxtehude, Buxtehude, Germany
[14] Gustave Roussy, Villejuif, France
[15] Paris Sud Univ, Villejuif, France
[16] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[17] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[18] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[19] Dana Farber Canc Inst, Boston, MA 02115 USA
[20] VCU Massey Canc Ctr, Richmond, VA USA
[21] Maria Sklodowska Curie Inst, Warsaw, Poland
[22] Merck & Co Inc, Kenilworth, NJ USA
[23] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS9596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9596
引用
收藏
页数：2
相关论文
共 50 条
  • [1] KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
    Luke, Jason J.
    Ascierto, Paolo A.
    Carlino, Matteo S.
    Gershenwald, Jeffrey E.
    Grob, Jean-Jacques
    Hauschild, Axel
    Kirkwood, John M.
    Long, Georgina, V
    Mohr, Peter
    Robert, Caroline
    Ross, Merrick
    Scolyer, Richard A.
    Yoon, Charles H.
    Poklepovic, Andrew
    Rutkowski, Piotr
    Anderson, James R.
    Ahsan, Sama
    Ibrahim, Nageatte
    Eggermont, Alexander M. M.
    FUTURE ONCOLOGY, 2020, 16 (03) : 4429 - 4438
  • [2] Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.
    Luke, Jason J.
    Ascierto, Paolo Antonio
    Carlino, Matteo S.
    Eggermont, Alexander M. M.
    Grob, Jean-Jacques
    Hauschild, Axel
    Kirkwood, John M.
    Long, Georgina V.
    Mohr, Peter
    Robert, Caroline
    Gershenwald, Jeffrey E.
    Poklepovic, Andrew Stewart
    Ross, Merrick I.
    Scolyer, Richard A.
    Yoon, Charles
    Anderson, James R.
    Ahsan, Sama
    Ibrahim, Nageatte
    Sondak, Vernon K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [3] Adjuvant pembrolizumab versus placebo in resected high- risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
    Khattak, Muhammad A.
    Luke, Jason J.
    Long, Georgina V.
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Robert, Caroline
    Grob, Jean-Jacques
    Merino, Luis de la Cruz
    Del Vecchio, Michele
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Carlino, Matteo S.
    Mohr, Peter
    De Galitiis, Federica
    Ross, Merrick I.
    Eroglu, Zeynep
    Chen, Ke
    Jiang, Ruixuan
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M. M.
    Kirkwood, John M.
    EUROPEAN JOURNAL OF CANCER, 2022, 176 : 207 - 217
  • [4] Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study.
    Long, Georgina V.
    Luke, Jason J.
    Khattak, Muhammad
    Merino, Luis de la Cruz
    Del Vecchio, Michele
    Rutkowski, Piotr
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    de Galitiis, Federica
    Schadendorf, Dirk
    Carlino, Matteo S.
    Wu, Larry
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M.
    Ascierto, Paolo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [5] Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Tumor Location in the Phase 3 KEYNOTE-716 Study
    Yoon, Charles H.
    Ross, Merrick I.
    Gastman, Brian
    Luke, Jason J.
    Ascierto, Paolo A.
    Long, Georgina V.
    Rutkowski, Piotr
    Khattak, Muhammad
    Del Vecchio, Michele
    de la Cruz Merino, Luis
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Schadendorf, Dirk
    Carlino, Matteo S.
    Zhao, Yujie
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M. M.
    Gershenwald, Jeffrey E.
    Sondak, Vernon K.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S34 - S35
  • [6] Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
    Luke, Jason J.
    Rutkowski, Piotr
    Queirolo, Paola
    Del Vecchio, Michele
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    de la Cruz-Merino, Luis
    Khattak, Muhammad A.
    Schadendorf, Dirk
    Long, Georgina, V
    Ascierto, Paolo A.
    Mandala, Mario
    De Galitiis, Federica
    Haydon, Andrew
    Dummer, Reinhard
    Grob, Jean-Jacques
    Robert, Caroline
    Carlino, Matteo S.
    Mohr, Peter
    Poklepovic, Andrew
    Sondak, Vernon K.
    Scolyer, Richard A.
    Kirkwood, John M.
    Chen, Ke
    Diede, Scott J.
    Ahsan, Sama
    Ibrahim, Nageatte
    Eggermont, Alexander M. M.
    LANCET, 2022, 399 (10336): : 1718 - 1729
  • [7] Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study
    Long, G. V.
    Luke, J.
    Khattak, M. A.
    de la Cruz Merino, L.
    Del Vecchio, M.
    Rutkowski, P.
    Spagnolo, F.
    Mackiewicz, J.
    Chiarion-Sileni, V.
    Kirkwood, J. M.
    Robert, C.
    Grob, J. J.
    de Galitiis, F.
    Schadendorf, D.
    Carlino, M. S.
    Wu, L.
    Fukunaga-Kalabis, M.
    Krepler, C.
    Eggermont, A. M. M.
    Ascierto, P. A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 95 - 95
  • [8] Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
    Luke, Jason J.
    Ascierto, Paolo A.
    Khattak, Muhammad A.
    de la Cruz-Merino, Luis
    Del Vecchio, Michele
    Rutkowski, Piotr
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    de Galitiis, Federica
    Schadendorf, Dirk
    Carlino, Matteo S.
    Wu, Xi Lawrence
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M. M.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (14) : 1619 - 1624
  • [9] Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected highrisk stage II melanoma in the phase 3 KEYNOTE-716 study.
    Khattak, Muhammad Adnan
    Luke, Jason J.
    Long, Georgina V.
    Ascierto, Paolo Antonio
    Rutkowski, Piotr
    Schadendorf, Dirk
    Robert, Caroline
    Grob, Jean-Jacques
    Merino, Luis de la Cruz
    Del Vecchio, Michele
    Spagnolo, Francesco
    Mackiewicz, Jacek
    Chiarion-Sileni, Vanna
    Carlino, Matteo S.
    Mohr, Peter
    Jiang, Ruixuan
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander M.
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
    Schadendorf, Dirk
    Luke, Jason John
    Ascierto, Paolo A.
    Long, Georgina, V
    Rutkowski, Piotr
    Khattak, Adnan
    Del Vecchio, Michele
    de la Cruz-Merino, Luis
    Mackiewicz, Jacek
    Sileni, Vanna Chiarion
    Kirkwood, John M.
    Robert, Caroline
    Grob, Jean-Jacques
    Dummer, Reinhard
    Carlino, Matteo S.
    Zhao, Yujie
    Kalabis, Mizuho
    Krepler, Clemens
    Eggermont, Alexander
    Scolyer, Richard A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
12345